42 133

Cited 0 times in

Alterations of Coagulation and Fibrinolysis System in Lung Cancer

Other Title
폐암 환자에서 혈액 응고 및 섬유소 용해계의 이상
Authors
김, 형중; 김, 은숙; 안, 철민; 김, 성규; 이, 원영; 송, 경순; 박, 광주
Citation
The Korean journal of medicine, 54(4):467-472, 1998
Journal Title
The Korean journal of medicine; 대한내과학회지
ISSN
1738-93642289-0769
Abstract
Objectives : It is well known that malignant diseases exhibit an increased propensity

to clotting and fibrinolytic aberrations and early detection of these hemostatic alterations is very important for the rapid institution of appropriate treatment of thromboembolic and hemorrhagic complications in patients with malignant disease. The incidence of these abnormalities in lung cancer was reported from 20% up to 95% according to various investigators using different hemostatic parameters. We measured the concentrations of plasma thrombinantithrombin Ⅲ complex(TAT) and plasmin-α 2-plasmin inhibitor complex(PIC), which are newly developed sensitive

molecular markers of coagulation and fibrinolysis system respectively in patients with lung cancer and determined the degree of these hemostatic abnormalities according to the histologic types and different clinical stages in patients with lung cancer.

Methods : We measured the concentrations of plasma TAT and PIC in 62 patients

with histologically confirmed lung cancer, and we determined stage radiologically in

nonsurgical patients and pathologically in surgical patients. The plasma TAT and PIC

levels were assayed using a solid phase enzyme immunoassay with Enzygnost-TAT

kit(Behringwerke, Marburg, Germany) and Enzygnost-PAP kit(Behringwerke, Marburg,

Germany), respectively.

Results : The concentrations of plasma TAT(6.8±4.8ng/mL) and PIC(644.3±330.5

ng/mL) in Patients with lung cancer were significantly increased compared to those of

plasma TAT(2.8± 1.2 ng/mL) and PIC(240.4±69.7 ng/mL) in control subjects(p0.05).

Conclusions : There was a subclinical activation of coagulation and fibrinolysis system in patients with lung cancer although they don't have overt clinical evidences of

thromboembolism or hemorrhage. But there were no different activation of coagulation

and fiblinolysis system according to histologic types and clinical stages.
Keywords
Thrombin-antithrombin Ⅲ complex(TAT)Plasmin-α2-plasmin inhibitor complex(PIC)Lung cancer
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Pulmonary & Critical Care Medicine
Full Text Link
Files in This Item:
467-472.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse